silodosin (Rapaflo)
Jump to navigation
Jump to search
Introduction
FDA approved Oct 2008
Indications
Contraindications
Dosage
8 mg QD
Tabs: 4 mg, 8 mg Dosage adjustment in renal impairment:
- 4 mg QD for men with moderate renal impairment
- not recommended for men with severe renal or hepatic impairment
Adverse effects
- reduced semem during orgasm (most common)
- retrograde ejaculation, more common than with non-selective alpha-blockers
- dizziness, light-headedness, orthostatic hypotension
- diarrhea
- headache
- pharyngitis, nasal congestion
- risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery
- drug adverse effects of alpha-1 adrenergic receptor antagonists
- drug adverse effects of antihypertensive agents
Mechanism of action
- blocks alpha-1 receptors in the prostate, bladder, & urethra, relaxing smooth muscle
More general terms
References
- ↑ FDA News FDA Approves Rapaflo for the Treatment of Symptoms Due to an Enlarged Prostate Gland http://www.fda.gov/bbs/topics/NEWS/2008/NEW01902.html
- ↑ Prescriber's Letter 16(5) 2009 Comparison of Alpha1-Blockers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250505&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Deprecated Reference